Clinical trial
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
NCT04093622 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
- Lead sponsor
- Fate Therapeutics
- Phase
- Observational
- Overall status
- Terminated
- Start date
- October 4, 2019
- Completion date
- April 9, 2020
- Enrollment
- 2 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
hematological malignancy